One of the most common questions I receive in my vasculitis clinic is one of the most difficult to answer: “When can we stop rituximab?” While we know everyone needs therapy for at least one year and have reasonably good data for 18 months, whether folks should continue after that remains an open question. That is why I was especially excited to see a post hoc analysis of RITAZAREM, which followed patients for up to 48 months from enrollment.
All News
Article
Article
While there is plenty to watch this ACR in the maturing CAR-T space, one of the big global stories in the second half of 2026 has been about zola-cel and the pause in the Breakfree program.
David Liew
Tweet
PD-1 agonists & RA:
peresolimab ph2b failed safety/efficacy
rosnilimab ph2b better for both
how confident on efficacy?
translational shows it's deeper where it counts
do differences matter?
(membrane proximal, ligand sparing, ?dual action)
we will see
ABST0868 #ACR26 @RheumNow https://t.co/P3FjrUKhwE
TARA study from China - Ph2 H2H Girocitinib (JAK1/TYK2i) vs Tofacitinib in active RA refractory to bDMARDS. 459 pts, ACR50 @wk 24 Giro 73% vs Tofa 49% (p<0.0001), also superior at ACR20, ACR70, DAS remission, CDAI<10. H.Zoster 3%. Abst#LB21 #ACR26 https://t.co/JZLjQx4vSa https://t.co/51gaIOKTWf
Janet Pope
Tweet
Impt pathway for #fibrosis & #inflammation?
FIbrosis in #sarcoidosis mediated thru
#TL1A
Myeloid cells —granulomas
TL1A effects
TNF
IL1beta
IL6
IL17
Drugs could be effective
Some already in #IBD
Ex
#Tulisokibart
#Duvakitug
#Afimkibart
🤷
#O019 #ACR26 @RheumNow @ACRheum https://t.co/GPKwEqWFkh
Janet Pope
Tweet
Rx of calcinosis in #SSc is ‘hard’
Small RCT of BID topical #sodium #metabiosulfite v #PBO
neg #trial but a trend to some imaging improvement at 4 mo
Tough trial to do
?need:
Larger, longer study
Higher dose?
Try sodium #thiosulfate instead
#0226
#ACR26 @ACRheum @RheumNow https://t.co/CyA1k4rnNr
Janet Pope
Tweet
Use deep B cell depletion in #diffuse #scleroderma if #rituximab fails?
🤞
Small case series from France showed #obinutuzimab seemed to be well tolerated and reduced #skin #score #mRSS post #RTX which was d/c for loss of effect or infusion rx’n
Need RCT
@RheumNow #0222 #ACR26 https://t.co/iEv2T4XcYS
Janet Pope
Tweet
‘Strong’ data in #myositis #0904 #Efgartigimod ⬇️Igs &#Abs LB +ph3 #RCT -👍on Wed #0905 #nipocalimab in #IIM also #FcRn #0906 #ruxolitinib ⬆️#survival in severe #MDA5 - but not RCT #0907 +RCT IIM #Brepocitinib ☑️clinical remission ☑️HAQ ☑️LDA #ACR26 #ACRbest @RheumNow
More TNFi biosims..why not??
Golimumab SubQ and IV biosimilars with interchangeable status coming soon!
#ACR26 @RheumNow https://t.co/fwJ21VI9CO
sheila
Tweet
For SLE pts with APS experiencing VMS like hot flashes sec to menopause, HT should be avoided.
Instead, non-hormonal options can be given like gabapentin, oxybutynin, SSRIs and neurokini antagonists.
@RheumNow #ACR26 https://t.co/T7QdNBoglw
Five FDA approved biosimilars in 2026 #ACR27 @FDA https://t.co/lIrtbtz7ts
Antoni Chan MD (Prof)
Tweet
Our poster: 22 years of axSpA advanced therapy in Reading, 431 patients. Adalimumab and etanercept showed the longest persistence. Key finding: 74% remained on a single advanced therapy, 7% needed three or more, and within class TNFi cycling was the most common switching pattern. https://t.co/6lIghVn8rh
Antoni Chan MD (Prof)
Tweet
INSPIRE 2, tildrakizumab 100 mg every 12 weeks in TNFi naive PsA (n=296): at week 24, ACR20 34.8% vs 22.7%, ACR50 22.3% vs 14.4% and PASI 75 31.6% vs 11.1% with placebo. Key finding: the primary endpoint was met, responses improved to week 52 (ACR20 about 62%), and no new safety
Antoni Chan MD (Prof)
Tweet
Crusekitug, a new IL17A antibody, phase 3 in AS (n=641): ASAS40 at week 16 was 40.4% vs 18.9% with placebo, and ASAS20 65.2% vs 41.2%. Spinal and sacroiliac MRI inflammation fell more than with placebo. Key finding: crusekitug improved signs, symptoms and MRI inflammation, with
Antoni Chan MD (Prof)
Tweet
Izokibep, a novel IL17A inhibitor, phase 2b/3 in PsA (n=343): week 16 ACR50 was 41% to 46% vs 18% with placebo in TNFi naive patients, and 33% to 37% vs 7% after prior TNFi. Key finding: responses exceeded placebo across all subgroups studied and were maintained or improved to
Janet Pope
Tweet
#FcRn fails in #SjD
+ early phase results ‘dry’ up in Phase3 #efgartigimod in #Sjogren’s #disease
Will await late breaking + #inflammatory #myositis with efgartigimod @ACRheum #ACR26
abst#LB24
@RheumNow https://t.co/EnOEXuW6jf
anita
Tweet
@RheumNow #ACR2026 Abstract #0129 (Poster)
The Lupus Gene Curation Expert Panel (GCEP) evaluated 55 genes implicated in monogenic lupus using ClinGen’s clinical validity framework. 5 genes achieved definitive gene–disease association: C1QA, C1QB, C1QC, DNASE1L3 and PRKCD.
Successful antibody suppression from efgartigimod (blocks FcRn-mediated IgG recycling)
Cell data from 89-pt phase 2 ALKIVIA study, total IgG lowered along with myositis-specific antibody signals (IMN & asys)
Need to see clinical data & reducing ab's doesn't always translate to https://t.co/Hl5OP9zH0m
Eric Dein
Tweet
#ACR26 @RheumNow
Ab#0448 Addition of Nintedanib to Abatacept in RA-ILD
80 pts progressive ILD, 263 non-progressive. NNTE added to 6 prog, 13 non-prog
Non-prog- no signif results
In prog RA-ILD, ABA+NINTE showed stabilized FVC on f/u over 48 mo https://t.co/MPpzqT4ajr
